Given the frequent overexpression of CD70 in RCC, particularly in ccRCC, CD70‐targeted immuno‐PET/CT may help overcome the limitations of conventional 18F‐FDG PET/CT in RCC by addressing issues such as low tracer uptake in certain lesions and the challenge of distinguishing inflammation as well as benign and malignant tumours6, 7, 8 (Figure 2). The gene discussed is CD70; the disease is nonpapillary renal cell carcinoma.